CDIO
Cardio Diagnostics Holdings, Inc.3.0950
+0.0150+0.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.65MP/E (TTM)
-Basic EPS (TTM)
-11.91Dividend Yield
0%Recent Filings
8-K
Investor call on updates
Cardio Diagnostics held an investor call on February 19, 2026, discussing corporate updates, recent clinical data, reimbursement progress, and strategic priorities. Highlights include launching an internal CLIA lab for ~30% COGS reduction and 7-10 day TAT, alongside partnerships in India for global expansion. Forward-looking statements carry risks detailed in SEC filings.
10-Q
Q3 FY2025 results
Cardio Diagnostics posted Q3 revenue of $2,855, down 57% y/y from $6,580 yet narrowing operating loss to $1.7M from $1.4M as SG&A climbed on R&D and sales investments. Nine-month revenue fell to $11,270 from $30,378 y/y, but net loss improved to $5.0M from $6.9M, thanks to lower stock-based comp. Cash burned $4.4M in operations; $6.4M remains on hand after $3.2M net equity raises. No debt weighs the balance sheet. Diluted EPS reconciles at -$0.98 on 1.76M shares. Litigation tails from old deals linger.
8-K
Annual meeting proposals approved
Cardio Diagnostics stockholders approved all three proposals at the October 15, 2025 annual meeting, with 52.6% turnout from 1,763,129 eligible shares. Seven directors elected on plurality votes; future non-public share issuances exceeding 20% outstanding cleared narrowly (283k for, 166k against). Prager Metis ratified as auditors. Board continuity secured.
10-Q
Q2 FY2025 results
Cardio Diagnostics posted Q2 revenue of $7,475, flat y/y from $7,870 while YTD revenue fell to $8,415 from $23,798 after a key testing initiative wrapped. Operating loss widened to $1.7M from $1.3M on higher payroll, R&D, and sales expenses, matching net loss as other items stayed minor. Cash holds steady at $8.0M after $3.2M raised via stock sales offset $3.0M operating burn; finance agreement payable down to $77K. No capex details limit FCF view. Reverse split boosted shares to 1.74M, aligning EPS at -$0.97. Litigation tails linger.
8-K
Regains Nasdaq compliance
Cardio Diagnostics Holdings regained Nasdaq compliance on May 28, 2025, after its common stock closed at or above $1.00 for 10 straight business days from May 13-27. This follows a second 180-day extension granted in December 2024, resolving the bid price deficiency under Rule 5550(a)(2). Compliance secured. No further details on strategy disclosed.
BJDX
Bluejay Diagnostics, Inc.
0.97-0.04
CAI
Caris Life Sciences, Inc.
27.60+0.90
CODX
Co-Diagnostics, Inc.
0.25-0.02
CSTL
Castle Biosciences, Inc.
39.05+0.17
CVKD
Cadrenal Therapeutics, Inc.
8.25-4.04
HSCS
HeartSciences Inc.
2.31-0.16
IBIO
iBio, Inc.
2.06+0.23
LUCD
Lucid Diagnostics Inc.
1.12+0.01
PRPO
Precipio, Inc.
24.02-0.04
YDES
YD Bio Limited
12.62+0.22